Engaged in the research of high-tech new drugs of traditional Chinese medicine for many years. During the Seventh Five-Year Plan and the Eighth Five-Year Plan, he designed and presided over the key research project of the Ministry of Health and state administration of traditional chinese medicine "Coix seed ester preparation and its anticancer mechanism and clinical research". Kanglaite injection is an important achievement of this research, which fills the blank of intravenous emulsion of biphasic anticancer Chinese medicine at home and abroad, and is praised as one of the "three breakthrough achievements in the modern development history of Chinese medicine" by relevant experts. This achievement was identified as "national key new product" by the state, won the third prize of national invention, the first prize of ministerial scientific and technological progress and the second prize of new drug research and development, and was listed as "A-level project" of the national new drug research and development fund, the key project of the national torch plan, the "double-addition project" of the State Economic and Trade Commission and the "Ninth Five-Year Plan" of the State Science and Technology Commission. Inventive technologies and drugs have been patented in China, the United States and other countries. In order to industrialize high-tech achievements, Zhejiang Kanglaite Pharmaceutical Co., Ltd. was established and listed as a "national key high-tech enterprise". Kanglaite injection is currently applying to FDA to enter the mainstream drug market in the United States. He also presided over a number of high-tech innovative research topics of traditional Chinese medicine, such as "industrial application research of supercritical carbon dioxide extraction in the field of traditional Chinese medicine", "anti-liver cancer research of coix seed ester iodized oil" and "research on Kanglaite soft capsule preparation".